Gulf Resources Inc. CEO Mr. Ming Yang commented, "This contemplated relationship is aimed at leveraging SYCI's core research and development competencies with our bromine production capabilities to segway into new compounds utilized in pharmaceutical products. Currently, only four companies possess the T.M.B. formula and Professor Ji, our partner from East China University of Science and Technology is the fourth. Our recently signed partnership enables us to utilize this formula for commercialization. Establishing a relationship with a large, well established Company like Southwest Synthetic Pharmaceutical Corporation Ltd. is an endorsement for our entire organization and our new research capabilities. Currently Southwest Synthetic Pharmaceutical utilizes approximately 500 tons of T.M.B annually, equating to approximately $7.5 million in product purchases. Further, our research shows that global demand for T.M.B's is approximately 5,000 tons while current production supply is between 3,500 and 4,000 tons, creating additional opportunities to gain market share."

Founded in 1965 and based in Chongqing City, Southwest Synthetic Pharmaceutical Corporation Ltd. is one of the largest developers, manufacturers and exporters of pharmaceuticals in West China. The Company was listed on the Shenzhen Stock Exchange in 1997 with the trading code 000788 and in 2006 its revenues were $65 million.
 

Southwest Synthetic Pharmaceutical Corporation Ltd. produces a broad portfolio of both bulk pharmaceuticals and preparation compounds through its GMP certified facility. Four of its products are approved by U.S. FDA, including Sulfamethazine, Trimethoprim, Sulfamethoxazole, Sulfamethazine Sodium, and another four have been registered in the European Directorate for the Quality of Medicines, including Sulfadimidine, Trimethoprim, Sulfamethoxazole, and Sulfadiazine. The Company also maintains products registered and approved in Canada, Russia, and India.